Identification of Gene and Protein Markers of Kidney Injury in Aminoglycoside-Treated Children

• Register: ClinicalTrials.gov
• Last refreshed on: 17 October 2012
• Main ID: NCT00308906
• Date of registration: 29/03/2006
• Primary sponsor: Virginia Commonwealth University
• Public title: Identification of Gene and Protein Markers of Kidney Injury in Aminoglycoside-Treated Children
• Scientific title: Assessment of Gene and Urinary Protein Expression in Aminoglycoside-Treated and Untreated Infants, Children and Adolescents
• Date of first enrolment: June 2006
• Target sample size: 166
• Recruitment status: Suspended
• URL: http://clinicaltrials.gov/show/NCT00308906
• Study type: Observational
• Study design: Observational Model: Case Control, Time Perspective: Prospective

Countries of recruitment

United States

Contacts

• Name: Mary Jayne Kennedy, Pharm.D.
• Affiliation: Virginia Commonwealth University

Key inclusion & exclusion criteria

Inclusion Criteria: (1) Hospitalized male and female newborns, infants, children and
adolescents (ages birth to 18 years) with a diagnosis of suspected or proven bacterial
sepsis, meningitis or other indication necessitating aminoglycoside therapy (2)
hospitalized and outpatient newborns, infants, children and adolescents (ages birth to 18
years) who are not receiving aminoglycoside therapy.

Exclusion Criteria: (1) Current treatment with inhaled or ophthalmic aminoglycosides (2)
Prior treatment with an aminoglycoside within the last 30 days



Age minimum: N/A
Age maximum: 18 Years
Gender: Both

Health Condition(s) or Problem(s) studied

Infection

Renal Dysfunction

Intervention(s)

Drug: aminoglycoside

Secondary ID(s)

Aminoglycoside Waste Specimen

Source(s) of Monetary Support

Please refer to primary and secondary sponsors

Secondary Sponsor(s)

University of Louisville